SNY vs. REGN

Last updated Jun 3, 2026

SNY (Sanofi) and REGN (Regeneron Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — SNY in Drug Manufacturers - General, REGN in Biotechnology. Over the past 10 years, SNY returned 4.63%/yr vs 4.25%/yr for REGN. At a 0.30 correlation, their price movements are largely independent.

Performance

SNY vs. REGN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, SNY achieves a -6.78% return, which is significantly higher than REGN's -21.68% return. Over the past 10 years, SNY has outperformed REGN with an annualized return of 4.63%, while REGN has yielded a comparatively lower 4.25% annualized return.

SNY

• 1D: -0.37%
• 1M: -1.96%
• YTD: -6.78%
• 6M: -9.38%
• 1Y: -8.16%
• 3Y*: -1.21%
• 5Y*: 0.44%
• 10Y*: 4.63%

REGN

• 1D: 0.38%
• 1M: -13.91%
• YTD: -21.68%
• 6M: -18.52%
• 1Y: 23.51%
• 3Y*: -6.34%
• 5Y*: 3.75%
• 10Y*: 4.25%

*Multi-year figures are annualized to reflect compound growth (CAGR)

SNY vs. REGN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
SNY Sanofi	-6.78%	4.93%	1.09%	6.55%	0.57%	7.00%	0.39%	20.47%	6.06%	9.96%
REGN Regeneron Pharmaceuticals, Inc.	-21.68%	8.96%	-18.90%	21.73%	14.25%	30.72%	28.66%	0.53%	-0.65%	2.42%

Correlation

The correlation between SNY and REGN is 0.38, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.38
Correlation (3Y) Calculated over the trailing 3-year period	0.35
Correlation (5Y) Calculated over the trailing 5-year period	0.35
Correlation (10Y) Calculated over the trailing 10-year period	0.35
Correlation (All Time) Calculated using the full available price history since Jul 2, 2002	0.30

Fundamentals

Market Cap SNY : $103.08B REGN : $64.93B
EPS SNY : $3.09 REGN : $41.05
PE Ratio SNY : 13.86 REGN : 14.69
PS Ratio SNY : 2.21 REGN : 4.35
PB Ratio SNY : 1.42 REGN : 2.07
Total Revenue (TTM) SNY : $47.35B REGN : $14.92B
Gross Profit (TTM) SNY : $34.18B REGN : $12.61B
EBITDA (TTM) SNY : $12.63B REGN : $5.74B

Return for Risk

SNY vs. REGN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SNY

SNY Risk / Return Rank: 23
SNY Sharpe Ratio Rank: 27
SNY Sortino Ratio Rank: 24
SNY Omega Ratio Rank: 23
SNY Calmar Ratio Rank: 23
SNY Martin Ratio Rank: 19

REGN

REGN Risk / Return Rank: 61
REGN Sharpe Ratio Rank: 63
REGN Sortino Ratio Rank: 58
REGN Omega Ratio Rank: 57
REGN Calmar Ratio Rank: 60
REGN Martin Ratio Rank: 68

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SNY vs. REGN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	SNY	REGN	Difference
Sharpe ratio Return per unit of total volatility	-0.33	0.72	-1.05
Sortino ratio Return per unit of downside risk	-0.28	1.23	-1.51
Omega ratio Gain probability vs. loss probability	0.96	1.15	-0.19
Calmar ratio Return relative to maximum drawdown	-0.51	0.91	-1.42
Martin ratio Return relative to average drawdown	-1.01	3.30	-4.32
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

SNY vs. REGN - Sharpe Ratio Comparison

The current SNY Sharpe Ratio is -0.33, which is lower than the REGN Sharpe Ratio of 0.72. The chart below compares the historical Sharpe Ratios of SNY and REGN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	SNY	REGN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.33	0.72	-1.05
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.02	0.12	-0.10
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.20	0.13	+0.07
Sharpe Ratio (All Time) Calculated using the full available price history	0.20	0.16	+0.05

Drawdowns

SNY vs. REGN - Drawdown Comparison

The maximum SNY drawdown since its inception was -46.46%, smaller than the maximum REGN drawdown of -91.81%. Use the drawdown chart below to compare losses from any high point for SNY and REGN.

Drawdown Indicators

	SNY	REGN	Difference
Max Drawdown Largest peak-to-trough decline	-46.46%	-91.81%	+45.35%
Max Drawdown (1Y) Largest decline over 1 year	-16.70%	-25.85%	+9.15%
Max Drawdown (3Y) Largest decline over 3 years	-23.37%	-59.69%	+36.32%
Max Drawdown (5Y) Largest decline over 5 years	-33.52%	-59.69%	+26.17%
Max Drawdown (10Y) Largest decline over 10 years	-33.52%	-59.69%	+26.17%
Current Drawdown Current decline from peak	-20.60%	-49.42%	+28.82%
Average Drawdown Average peak-to-trough decline	-12.19%	-42.38%	+30.19%
Ulcer Index Depth and duration of drawdowns from previous peaks	8.39%	7.16%	+1.23%

Volatility

SNY vs. REGN - Volatility Comparison

The current volatility for Sanofi (SNY) is 5.39%, while Regeneron Pharmaceuticals, Inc. (REGN) has a volatility of 12.02%. This indicates that SNY experiences smaller price fluctuations and is considered to be less risky than REGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SNY	REGN	Difference
Volatility (1M) Calculated over the trailing 1-month period	5.39%	12.02%	-6.63%
Volatility (6M) Calculated over the trailing 6-month period	14.94%	22.49%	-7.55%
Volatility (1Y) Calculated over the trailing 1-year period	24.93%	32.72%	-7.79%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	24.68%	30.75%	-6.07%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	23.42%	32.16%	-8.74%

Dividends

SNY vs. REGN - Dividend Comparison

SNY's dividend yield for the trailing twelve months is around 5.66%, more than REGN's 0.60% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
REGN Regeneron Pharmaceuticals, Inc.	0.60%	0.46%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SNY Sanofi	5.66%	4.56%	4.22%	3.83%	4.32%	3.80%	3.61%	3.47%	4.29%	3.82%	4.11%	3.77%

Financials

SNY vs. REGN - Profitability Comparison

The chart below illustrates the profitability comparison between Sanofi and Regeneron Pharmaceuticals, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

SNY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Sanofi reported a gross profit of 8.11B and revenue of 11.24B. Therefore, the gross margin over that period was 72.1%.

REGN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a gross profit of 2.94B and revenue of 3.61B. Therefore, the gross margin over that period was 81.4%.

SNY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Sanofi reported an operating income of 2.27B and revenue of 11.24B, resulting in an operating margin of 20.2%.

REGN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported an operating income of 642.90M and revenue of 3.61B, resulting in an operating margin of 17.8%.

SNY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Sanofi reported a net income of 1.61B and revenue of 11.24B, resulting in a net margin of 14.4%.

REGN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a net income of 727.20M and revenue of 3.61B, resulting in a net margin of 20.2%.

Frequently Asked Questions

Can I hold both SNY and REGN in my portfolio?

SNY and REGN have a correlation of 0.38, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, SNY or REGN?

REGN has higher volatility (12.02%) compared to SNY (5.39%). In terms of maximum drawdown, SNY dropped -46.46% vs REGN's -91.81%.

Which has better risk-adjusted returns?

REGN currently has the higher Sharpe Ratio (0.72 vs -0.33), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.